171 related articles for article (PubMed ID: 24581432)
1. Use of omalizumab to improve desensitization safety in allergen immunotherapy.
Larenas-Linnemann D; Wahn U; Kopp M
J Allergy Clin Immunol; 2014 Mar; 133(3):937-937.e2. PubMed ID: 24581432
[No Abstract] [Full Text] [Related]
2. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma.
Lambert N; Guiddir T; Amat F; Just J
Pediatr Allergy Immunol; 2014 Dec; 25(8):829-32. PubMed ID: 25387446
[No Abstract] [Full Text] [Related]
3. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities.
Rizk C; Ring A; Santucci S; MacLusky I; Karsh J; Yang WH
Ann Allergy Asthma Immunol; 2012 Sep; 109(3):222-3. PubMed ID: 22920081
[No Abstract] [Full Text] [Related]
4. [Nearly uncontrollable hyperreactivity. Last options in bronchial asthma].
Füesl HS; Stiefelhagen P
MMW Fortschr Med; 2014 Mar; 156(5):17. PubMed ID: 24912253
[No Abstract] [Full Text] [Related]
5. How do we interpret the data supporting the use of omalizumab for severe asthma?
Lavietes MH
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):335-6. PubMed ID: 25256024
[No Abstract] [Full Text] [Related]
6. Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report.
Di Stefano F; Cinti B; Antonicelli L
Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):56-9. PubMed ID: 24702879
[TBL] [Abstract][Full Text] [Related]
7. Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
Owens G; Petrov A
Curr Drug Saf; 2011 Nov; 6(5):339-42. PubMed ID: 22424542
[TBL] [Abstract][Full Text] [Related]
8. Allergic bronchopulmonary aspergillosis and omalizumab.
Tillie-Leblond I; Germaud P; Leroyer C; Tétu L; Girard F; Devouassoux G; Grignet JP; Prudhomme A; Dusser D; Wallaert B
Allergy; 2011 Sep; 66(9):1254-6. PubMed ID: 21517902
[No Abstract] [Full Text] [Related]
9. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
10. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma.
Tajiri T; Matsumoto H; Hiraumi H; Ikeda H; Morita K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Ito J; Niimi A; Mishima M
Ann Allergy Asthma Immunol; 2013 May; 110(5):387-8. PubMed ID: 23622013
[No Abstract] [Full Text] [Related]
13. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab: a novel steroid sparing agent in eosinophilic granulomatosis with polyangiitis?
Latorre M; Baldini C; Seccia V; Notarstefano C; Della Rossa A; Tani C; Talarico R; Mosca M; Paggiaro PL
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S91-2. PubMed ID: 23075542
[No Abstract] [Full Text] [Related]
15. [Programs for continuing medical education: A session; 7. Current topics of asthma treatment--anti-IgE therapy].
Adachi M; Tanaka A
Nihon Naika Gakkai Zasshi; 2012 Mar; 101(3):689-93. PubMed ID: 22620037
[No Abstract] [Full Text] [Related]
16. Omalizumab: just what we needed.
Torres-Borrego J
Allergol Immunopathol (Madr); 2014; 42(1):1-2. PubMed ID: 24529608
[No Abstract] [Full Text] [Related]
17. The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.
Yalcin AD; Bisgin A
Med Sci Monit; 2012 Aug; 18(8):LE9-10. PubMed ID: 22847211
[No Abstract] [Full Text] [Related]
18. Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit.
Cazzola M; Segreti A
Drugs; 2014 Apr; 74(5):535-7. PubMed ID: 24691708
[No Abstract] [Full Text] [Related]
19. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
Aksu K; Kurt E
Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
[No Abstract] [Full Text] [Related]
20. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
Huffaker MF; Phipatanakul W
Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
